These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 38798011)
1. Serum (-2)proPSA/freePSAratio, (-2)proPSA/freePSA density, prostate health index, and prostate health index density as clues to reveal postoperative clinically significant prostate cancer in men with prostate-specific antigen 2-10 ng/mL. Ferro M; Crocetto F; La Civita E; Fiorenza M; Jannuzzi G; Carbone G; Sirica R; Sicignano E; Pagano G; Imbimbo C; Terracciano D Prostate; 2024 Sep; 84(12):1157-1164. PubMed ID: 38798011 [TBL] [Abstract][Full Text] [Related]
2. Prostate health index density predicts aggressive pathological outcomes after radical prostatectomy in Taiwanese patients. Huang YP; Lin TP; Cheng WM; Wei TC; Huang IS; Fan YH; Lin CC; Huang EYH; Chung HJ; Kuo JY; Wu HHH; Lu SH; Chang YH; Lin ATL; Huang WJS J Chin Med Assoc; 2019 Nov; 82(11):835-839. PubMed ID: 31425303 [TBL] [Abstract][Full Text] [Related]
3. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841 [TBL] [Abstract][Full Text] [Related]
4. Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection. Chiu ST; Cheng YT; Pu YS; Lu YC; Hong JH; Chung SD; Chiang CH; Huang CY Front Oncol; 2021; 11():772182. PubMed ID: 34869007 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study. Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975 [TBL] [Abstract][Full Text] [Related]
6. Comparisons of the diagnostic accuracy across prostate health index, prostate health index density, and percentage free prostate-specific antigen for clinically significant prostate cancer: a prospective diagnostic study. Wu B; Shao Y; Lin X; Hasi C; Jia W; Wang D; Cao X Transl Androl Urol; 2023 Mar; 12(3):425-432. PubMed ID: 37032752 [TBL] [Abstract][Full Text] [Related]
7. Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study. Fossati N; Buffi NM; Haese A; Stephan C; Larcher A; McNicholas T; de la Taille A; Freschi M; Lughezzani G; Abrate A; Bini V; Palou Redorta J; Graefen M; Guazzoni G; Lazzeri M Eur Urol; 2015 Jul; 68(1):132-8. PubMed ID: 25139197 [TBL] [Abstract][Full Text] [Related]
8. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study. Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786 [TBL] [Abstract][Full Text] [Related]
9. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years. Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705 [TBL] [Abstract][Full Text] [Related]
10. Preoperative prostate health index predicts adverse pathology and Gleason score upgrading after radical prostatectomy for prostate cancer. Novak V; Vesely S; Luksanová H; Prusa R; Capoun O; Fiala V; Dolejsová O; Sedlacková H; Kucera R; Stejskal J; Zalesky M; Babjuk M BMC Urol; 2020 Sep; 20(1):144. PubMed ID: 32894109 [TBL] [Abstract][Full Text] [Related]
11. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination. Lazzeri M; Abrate A; Lughezzani G; Gadda GM; Freschi M; Mistretta F; Lista G; Fossati N; Larcher A; Kinzikeeva E; Buffi N; Dell'Acqua V; Bini V; Montorsi F; Guazzoni G Urology; 2014 Mar; 83(3):606-12. PubMed ID: 24315305 [TBL] [Abstract][Full Text] [Related]
12. Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA <10 ng/mL: Largest prospective cohort in Taiwan. Fan YH; Pan PH; Lin TP; Huang TH; Wei TC; Huang IS; Lin CC; Huang EYH; Chung HJ; Huang WJS J Chin Med Assoc; 2019 Oct; 82(10):772-777. PubMed ID: 31356566 [TBL] [Abstract][Full Text] [Related]
13. A prospective study of the prostate health index density and multiparametric magnetic resonance imaging in diagnosing clinically significant prostate cancer. Chen Y; Xu D; Ruan M; Li H; Lin G; Song G Investig Clin Urol; 2023 Jul; 64(4):363-372. PubMed ID: 37417561 [TBL] [Abstract][Full Text] [Related]
14. The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center. Cheng YT; Chiang CH; Pu YS; Liu SP; Lu YC; Chang YK; Chang HC; Huang KH; Lee YJ; Chow PM; Hung SC; Huang CY J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):260-267. PubMed ID: 29779925 [TBL] [Abstract][Full Text] [Related]
15. Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study. Fossati N; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Lughezzani G; Gadda GM; Lista G; Larcher A; Abrate A; Mistretta F; Bini V; Redorta JP; Graefen M; Guazzoni G BJU Int; 2015 Jun; 115(6):913-20. PubMed ID: 24589357 [TBL] [Abstract][Full Text] [Related]
16. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961 [TBL] [Abstract][Full Text] [Related]
17. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333 [TBL] [Abstract][Full Text] [Related]
18. Prostate Health Index and %p2PSA Predict Aggressive Prostate Cancer Pathology in Chinese Patients Undergoing Radical Prostatectomy. Chiu PK; Lai FM; Teoh JY; Lee WM; Yee CH; Chan ES; Hou SM; Ng CF Ann Surg Oncol; 2016 Aug; 23(8):2707-14. PubMed ID: 26965697 [TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022 [TBL] [Abstract][Full Text] [Related]